Generated by AI
GSK plc ADR is an American depositary receipt representing two ordinary shares of GSK plc, a United Kingdom-based biopharmaceutical company. It provides U.S. investors with access to GSK’s healthcare business through a US-traded instrument tied to the company’s underlying ordinary shares. GSK focuses on pharmaceuticals, vaccines, and specialty medicines, with commercial activity centered on respiratory, immunology and inflammation, oncology, HIV, and infectious diseases. Its current portfolio includes products used in areas such as asthma, cancer, autoimmune disorders, and infectious disease prevention and treatment. The company operates through Commercial Operations and Research and Development, combining drug development with global commercialization of approved therapies. GSK plc ADR plays a role in the market as a widely followed healthcare security that reflects the performance of a multinational medicines and vaccines business with established reach across major therapeutic categories.
Website79 New Oxford Street
London, WC1A 1DG
United Kingdom
The latest articles about GSK.
Detailed price information for Gsk Plc ADR (GSK-N) from The Globe and Mail including charting and trades.
GSK plc (LSE:GSK) has received accelerated approval from the US Food and Drug Administration (FDA) for Nelkarmi (neladalkib), a targeted treatment for adults with previously treated, locally advanced or metastatic ALK-positive non-small cell lung cancer (NSCLC). The approval covers patients who have previously received alectinib as their only ALK tyrosine kinase inhibitor (TKI), or at least two prior ALK inhibitors and platinum-based chemotherapy, in the unresectable locally advanced or metastat
Summary of Oct 28's posts. Generated by AI.
Summary of Jan 20's posts. Generated by AI.
Summary of Jun 17's posts. Generated by AI.
Summary of Oct 28's posts. Generated by AI.
Investors talking about GSK also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.